Patent ID: 9289392
Filing Date: 2016-03-22
CPC Classification: A61K,A61P

Claim Text:
1. An extended release pharmaceutical composition comprising from about 200 mg to about 1000 mg of entacapone or salts thereof, the entacapone being coated by or embedded in matrix with one or more hydrophilic or hydrophobic polymers for achieving extended release along with other pharmaceutically acceptable excipients selected from the group consisting of diluents, binders, disintegrants, lubricants and glidants; wherein the hydrophilic or hydrophobic polymers are selected from the group consisting of cellulose acetate propionate, ethyl cellulose, an alkyl alcohol, a wax, rosin, zein (prolamine from corn), povidone, kollidon SR, polyuronic acid salts, gellan gum, alkali metal salts of alginic acid or pectic acid, hydroxypropyl cellulose, hydroxy ethyl cellulose, hydroxypropyl methyl cellulose, polymerized gelatin, methacrylic acid copolymer type C NF, cellulose butyrate phthalate, cellulose hydrogen phthalate, cellulose propionate phthalate, polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose acetate, dioxypropyl methylcellulose succinate, carboxymethyl ethyl cellulose (CMEC), acrylic acid polymers and copolymers, methyl acrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate with copolymers of acrylic and methacrylic acid esters, Eudragit NE, Eudragit RL and, Eudragit RS; wherein the composition is an extended release pharmaceutical, which extends the release of entacapone or salts thereof from about 4 hours to about 6 hours.